Literature DB >> 14559878

Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.

Kenneth Offit1, Orna Levran, Brian Mullaney, Katherine Mah, Khedoudja Nafa, Sat Dev Batish, Raffaella Diotti, Hildegard Schneider, Amie Deffenbaugh, Thomas Scholl, Virginia K Proud, Mark Robson, Larry Norton, Nathan Ellis, Helmut Hanenberg, Arleen D Auerbach.   

Abstract

Fanconi anemia is an inherited disease characterized by bone marrow failure, congenital malformations, and predisposition to cancer. The breast cancer susceptibility gene BRCA2 was recently found to be associated with Fanconi anemia complementation group D1 (FA-D1). We examined four kindreds afflicted with Fanconi anemia for the presence of germline BRCA2 mutations. One kindred, of Ashkenazi Jewish ancestry, had five members who were diagnosed with breast cancer and two cousins who were BRCA2*6174delT/C3069X compound heterozygotes and had Fanconi anemia and brain tumors. In another kindred of Ashkenazi Jewish and Lithuanian Catholic ancestry, a child with Fanconi anemia and a medulloblastoma was a BRCA2*6174delT/886delGT compound heterozygote. Two other kindreds each contained a Fanconi anemia-afflicted child who developed medulloblastoma; one child was of Latin American ancestry and a compound heterozygote for BRCA2*I2490T/ 5301insA and the other was African American and a compound heterozygote for BRCA2*Q3066X/E1308X. Median age of the Fanconi anemia-afflicted children at brain tumor diagnosis was 3.5 years. The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association. Individuals who carry a germline BRCA2 mutation and who plan to have children with a partner of Ashkenazi Jewish descent should consider undergoing genetic counseling.

Entities:  

Mesh:

Year:  2003        PMID: 14559878     DOI: 10.1093/jnci/djg072

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  57 in total

1.  Molecular cross-talk among chromosome fragility syndromes.

Authors:  Jordi Surrallés; Stephen P Jackson; Maria Jasin; Michael B Kastan; Stephen C West; Hans Joenje
Journal:  Genes Dev       Date:  2004-06-15       Impact factor: 11.361

Review 2.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

Review 3.  Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  David J Hughes
Journal:  Fam Cancer       Date:  2008-02-19       Impact factor: 2.375

4.  Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24.

Authors:  Jung Min Kim; Younghoon Kee; Allan Gurtan; Alan D D'Andrea
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

5.  Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia.

Authors:  Richard Mitchell; John E Wagner; Betsy Hirsch; Todd E DeFor; Heather Zierhut; Margaret L MacMillan
Journal:  Br J Haematol       Date:  2013-10-30       Impact factor: 6.998

6.  BRCA2 is required for neurogenesis and suppression of medulloblastoma.

Authors:  Pierre-Olivier Frappart; Youngsoo Lee; Jayne Lamont; Peter J McKinnon
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

Review 7.  Mouse models of DNA double-strand break repair and neurological disease.

Authors:  Pierre-Olivier Frappart; Peter J McKinnon
Journal:  DNA Repair (Amst)       Date:  2008-05-23

Review 8.  DNA repair deficiency and neurological disease.

Authors:  Peter J McKinnon
Journal:  Nat Rev Neurosci       Date:  2009-01-15       Impact factor: 34.870

9.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.

Authors:  Daniel H Kim; Beth Crawford; John Ziegler; Mary S Beattie
Journal:  Fam Cancer       Date:  2008-10-15       Impact factor: 2.375

10.  Modeling cancer progression via pathway dependencies.

Authors:  Elena J Edelman; Justin Guinney; Jen-Tsan Chi; Phillip G Febbo; Sayan Mukherjee
Journal:  PLoS Comput Biol       Date:  2008-02       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.